Exploring the Other Side of Medication: A Patient Interview Study on Anti-PCSK9 Monoclonal Antibodies
{{output}}
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors demonstrate significant lipid-lowering effects, but the widespread use of anti-PCSK9 monoclonal antibodies remains limited. ... ...
